Answer
Tarlatamab has a terminal elimination half-life of approximately 10.6 days in patients with small cell lung cancer.
Sources for this answer
- IMDYLLTRA 1 milligram powder for concentrate and solution for solution for infusionAmgen Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 4Document updated
Sources checked